Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab as Adjuvant Therapy for Renal Cell Carcinoma
NCT03142334Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2017
- Primary completion
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Pembrolizumab Arm with Placebo Arm (2 arms). Primary endpoint: Disease-free Survival as Assessed by the Investigator at 42 months. Started Jun 2017; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03142334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03142334.